Form 8-K - Current report:
SEC Accession No. 0002022626-25-000005
Filing Date
2025-09-02
Accepted
2025-09-02 08:38:15
Documents
13
Period of Report
2025-09-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K upb-20250902.htm   iXBRL 8-K 56662
2 EX-99.1 upb-ex99_1.htm EX-99.1 34182
3 EX-99.2 upb-ex99_2.htm EX-99.2 1107
4 PDF COURTESY COPY upb-ex99_2.pdf EX-99.2 1507802
  Complete submission text file 0002022626-25-000005.txt   2192157

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT upb-20250902.xsd EX-101.SCH 26961
15 EXTRACTED XBRL INSTANCE DOCUMENT upb-20250902_htm.xml XML 5106
Mailing Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451
Business Address 890 WINTER STREET, SUITE 200 WALTHAM MA 02451 781-208-2466
Upstream Bio, Inc. (Filer) CIK: 0002022626 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42366 | Film No.: 251283123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)